Literature DB >> 5761914

Treatment of hypertension with propranolol.

B N Prichard, P M Gillam.   

Abstract

When used in the treatment of hypertension propranolol is at least of similar potency to bethanidine, guanethidine, and methyldopa. Propranolol does not produce postural or exercise hypotension and it seems that it is often more acceptable to patients than conventional drugs. It usually produces the best control of the supine blood pressure.A series of 109 hypertensive patients was treated with propranolol; in nine the drug was withdrawn. In 92 of the patients a supine or standing blood pressure of 100 mm. Hg or less was achieved. Eighty of the patients had previously been treated with other potent drugs, and close comparisons and prolonged follow-up in 17 patients showed that diastolic pressures of 100 mm. Hg or less were achieved in more patients after propranolol than with guanethidine, bethanidine, or methyldopa.Sensitivity to propranolol varies widely, and dosage should be increased gradually. The hypotensive effect often takes six to eight weeks to reach its maximum. Propranolol reduces cardiac output but may also act by reducing the cardiac component of pressor stimuli; as a result the baroreceptors gradually regulate the blood pressure at a lower level. It is contraindicated in patients with obstructive airways disease or in uncompensated heart failure.

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 5761914      PMCID: PMC1981816          DOI: 10.1136/bmj.1.5635.7

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  24 in total

1.  EFFECT OF A BETA-ADRENERGIC-BLOCKING AGENT, PROPRANOLOL, ON ASTHMATICS.

Authors:  R S MCNEILL
Journal:  Lancet       Date:  1964-11-21       Impact factor: 79.321

2.  A SPHYGMOMANOMETER FOR EPIDEMIOLOGISTS.

Authors:  G A ROSE; W W HOLLAND; E A CROWLEY
Journal:  Lancet       Date:  1964-02-08       Impact factor: 79.321

3.  CARCINOGENIC ACTION OF PRONETHALOL.

Authors:  G E PAGET
Journal:  Br Med J       Date:  1963-11-16

4.  Effect of propranolol in mild hypertension.

Authors:  J W Paterson; C T Dollery
Journal:  Lancet       Date:  1966-11-26       Impact factor: 79.321

5.  Effect of propranolol on elevated arterial blood pressure.

Authors:  D W Richardson; J Freund; A S Gear; H P Mauck; L W Preston
Journal:  Circulation       Date:  1968-04       Impact factor: 29.690

6.  Ineffectiveness of propranolol in hypertensive Jamaicans.

Authors:  G S Humphreys; D G Delvin
Journal:  Br Med J       Date:  1968-06-08

7.  Propranolol in the therapy of angina pectoris.

Authors:  P M Gillam; B N Prichard
Journal:  Am J Cardiol       Date:  1966-09       Impact factor: 2.778

8.  Three cases of severe hypertension controlled with propranolol.

Authors:  B N Prichard
Journal:  Proc R Soc Med       Date:  1968-05

9.  Propranolol in hypertension.

Authors:  B N Prichard; P M Gillam
Journal:  Am J Cardiol       Date:  1966-09       Impact factor: 2.778

10.  [Clinical evaluation of propranolol in the treatment of hypertension].

Authors:  A Baczko; B Dabrowska; B Wocial
Journal:  Pol Arch Med Wewn       Date:  1967
View more
  88 in total

Review 1.  Exercise metabolism and beta-blocker therapy. An update.

Authors:  A Head
Journal:  Sports Med       Date:  1999-02       Impact factor: 11.136

2.  A review of beta-blockers and their use in general practice.

Authors:  J C Davies
Journal:  J R Coll Gen Pract       Date:  1976-03

3.  Haemodynamic effects of beta-adrenorecptor blockers in hypertension.

Authors:  B Ablad; B Ljung; R Sannerstedt
Journal:  Drugs       Date:  1976       Impact factor: 9.546

Review 4.  Side effects and contraindications of beta-receptor blocking agents.

Authors:  H Lydtin
Journal:  Klin Wochenschr       Date:  1977-05-01

5.  Long-term effects of propranolol on tyrosine hydroxylase and dopamine-beta-hydroxylase in the superior cervical ganglia of the rabbit [proceedings].

Authors:  I W Chubb; A E Raine; E M Williams
Journal:  Br J Pharmacol       Date:  1976-11       Impact factor: 8.739

Review 6.  Hypertension: which beta-blocker?

Authors:  H J Waal-Manning
Journal:  Drugs       Date:  1976-12       Impact factor: 9.546

7.  The "top 50": a perspective on the BMJ drawn from the Science Citation Index.

Authors:  B Dixon
Journal:  BMJ       Date:  1990-10-03

Review 8.  Allopathy--the therapeutic legacy.

Authors:  G D Johnston
Journal:  Ir J Med Sci       Date:  1989-01       Impact factor: 1.568

9.  Contribution of atenolol, bendrofluazide, and hydrallazine to management of severe hypertension.

Authors:  R G Wilcox; J R Mitchell
Journal:  Br Med J       Date:  1977-08-27

10.  Dose-titrated, double-blind, cross-over comparison of a selective beta-blocker and methyldopa in the treatment of hypertension.

Authors:  P A Routledge; L V Zrinzo; J G Rao; R J Walden; D M Davies; M D Rawlins
Journal:  Eur J Clin Pharmacol       Date:  1977-03-11       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.